Xinyu Zhu

Ms. Xinyu Zhu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JWJin Wang
Jin Wang
XSXiangrong Song
Xiangrong Song
MWMeidan Wei
Meidan Wei
LQLexin Qin
Lexin Qin
QZQingyun Zhu
Qingyun Zhu
JLJianxiang Li
Jianxiang Li
Proteomics offers a robust method for quantifying proteins and elucidating their roles in cellular functions, surpassing the insights provided by transcriptomics. The Clinical Proteomic Tumor Analysis Consortium database, enriched with comprehensive cancer proteomics data including phosphorylation and ubiquitination profiles, alongside transcriptomics data from the Genomic Data Commons, allow for integrative molecular studies of cancer. The ProteoCancer Analysis Suite (PCAS), our newly developed R package and Shinyapp, leverages these resources to facilitate in-depth analyses of proteomics, phosphoproteomics, and transcriptomics, enhancing our understanding of the tumor microenvironment through features like immune infiltration and drug sensitivity analysis. This tool aids in identifying critical signaling pathways and therapeutic targets, particularly through its detailed phosphoproteomic analysis. To demonstrate the functionality of the PCAS, we conducted an analysis of GAPDH across multiple cancer types, revealing a significant upregulation of protein levels, which is consistent with its important biological and clinical significance in tumors, as indicated in our prior research. Further experiments were used to validate the findings performed using the tool. In conclusion, the PCAS is a powerful and valuable tool for conducting comprehensive proteomic analyses, significantly enhancing our ability to uncover oncogenic mechanisms and identify potential therapeutic targets in cancer research.

3 January 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
YQYue Qiu
Yue Qiu
YSYaqin Shi
Yaqin Shi
ZCZhujun Chao
Zhujun Chao
XZXinyu Zhu
Xinyu Zhu
YCYan Chen
Yan Chen
LLLinlin Lu
Linlin Lu
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.

26 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YSYaqin Shi
Yaqin Shi
LLLi Lin
Li Lin
XZXinyu Zhu
Xinyu Zhu
MWMengyao Wu
Mengyao Wu
CXCaihua Xu
Caihua Xu
KCKai Chen
Kai Chen
Background: Breast cancer remains a predominant malignancy among females globally, and the tumor microenvironment (TME) exerts a pivotal role in its progression. Despite notable advancements in diagnostic and therapeutic modalities, resistance to conventional therapies persists as a critical hurdle, underscoring the necessity of exploring TME-related prognostic biomarkers. Methods: To elucidate the role of the TME in breast cancer progression and identify potential prognostic biomarkers, we analyzed RNA-seq data from 1081 breast cancer cases and 99 normal controls to assess tumor-infiltrating immune cells (TICs) and stromal components. Differential gene expression analysis identified genes correlated with ImmuneScore and StromalScore. A protein–protein interaction (PPI) network was constructed, followed by univariate Cox regression to pinpoint survival-associated genes. JCHAIN, significantly linked to survival outcomes, was selected for further investigation. Gene Set Enrichment Analysis (GSEA) and TIC correlation analyses were performed to explore its associations with immune pathways. Additionally, immunohistochemistry (IHC) and multiplexed immunofluorescence (mIF) were performed on 61 clinical samples. Results: High ImmuneScore was associated with improved survival. Joining chain of multimeric IgA and IgM (JCHAIN) expression was notably reduced in tumor tissues, with low expression correlating with poorer prognosis. GSEA highlighted immune-related pathways enriched in high JCHAIN expression groups. TIC analysis revealed positive correlations with CD8+ T cells and M1 macrophages. IHC and mIF validations further confirmed decreased JCHAIN protein expression in tumor tissues, and higher JCHAIN expression was associated with increased M1 macrophage density. Conclusions: JCHAIN serves as a promising prognostic biomarker in breast cancer, reflecting immune activity within the TME, providing valuable insights into immune-stromal interactions and the therapeutic potential of JCHAIN.

Verified
Journal Article
Open access
PDF file
XZXinyu Zhu
Xinyu Zhu
BLBo Li
Bo Li
LQLexin Qin
Lexin Qin
TLTingting Liang
Tingting Liang
WHWentao Hu
Wentao Hu
JWJin Wang
Jin Wang
Lung adenocarcinoma (LUAD), the predominant subtype of non-small cell lung cancer (NSCLC), presents significant challenges in early diagnosis and personalized treatment. Recent research has focused on the role of the tumor microenvironment, particularly tumor-associated fibroblasts (CAFs), in tumor progression. This study systematically analyzed CAF immune infiltration-related genes to construct a prognostic model for LUAD, confirming its predictive value for patient outcomes. The risk score derived from CAF-related genes (CAFRGs) was negatively correlated with immune microenvironment scores and linked to the expression of immune checkpoint genes, indicating that high-risk patients may exhibit immune escape characteristics. Analysis via the TIDE tool revealed that low-risk patients had more active T-cell immune responses. The risk score also correlated with anti-tumor drug sensitivity, particularly to doramapimod. Notably, COX6A1 emerged as a key gene in the model, with its upregulation associated with immune cell infiltration and immune escape. Further in vitro experiments demonstrated that COX6A1 regulates LUAD cell migration, proliferation, and senescence, suggesting its role in tumor immune evasion. Additionally, further co-culture studies of lung cancer cells and fibroblasts revealed that COX6A1 knockdown promotes the expression of CAF-related cytokines, enhancing CAF infiltration. Overall, this study provides a foundation for personalized treatment of LUAD and highlights COX6A1 as a promising therapeutic target within the tumor immune microenvironment, guiding future clinical research.

2 June 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
JWJin Wang
Jin Wang
MWMeidan Wei
Meidan Wei
JZJiaxin Zhang
Jiaxin Zhang
XSXiangrong Song
Xiangrong Song
YHYaoyu Hu
Yaoyu Hu
JLJianxiang Li
Jianxiang Li
Cancer research is pivotal for understanding cancer biology, discovering new therapeutic targets, and advancing precision medicine. However, it faces challenges such as data complexity, dispersed analytical tools, and the lack of a unified platform. To address these issues, we developed the GEO Cancer Analysis Suite (GCAS), an R package and visualization interface via shinyApp. GCAS includes four main modules: differential gene expression analysis, correlation studies, pan-cancer analysis, and immune infiltration and drug sensitivity analysis. These modules facilitate the identification of potential cancer biomarkers, elucidation of gene regulatory networks, comprehensive multi-cancer analysis, and assessment of gene expression in relation to immune cell infiltration and drug sensitivity. Using GCAS, GAPDH was found to be upregulated in multiple lung cancer and breast datasets and positively correlated with the m6A regulatory gene IGF2BP3. Further in vitro assays suggested that IGF2BP3 regulates GAPDH mRNA stability. Immune infiltration analysis indicated a negative correlation between GAPDH expression and CD4 T cell infiltration scores. Drug sensitivity analysis revealed a significant negative correlation between GAPDH expression and sensitivity to EGFR-targeting drugs, particularly Erlotinib. GCAS is a crucial tool in cancer research, simplifying data analysis and enhancing the discovery of novel biomarkers, immune landscape profiles, and drug sensitivity predictions, significantly contributing to cancer research and precision medicine.